Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02269917 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants
A Phase 3 study, sponsored by Janssen R&D Ireland.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,149
- Enrollment target
NCT02269917 is a Phase 3 study that has completed, run by Janssen R&D Ireland. The registered enrollment target is 1,149 participants.
The verdict
NCT02269917, a Phase 3 study, has completed, sponsored by Janssen R&D Ireland.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,149 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate non-inferiority in efficacy while switching to a once-daily single-tablet regimen containing darunavir (DRV)/ cobicistat (COBI)/ emtricitabine (FTC)/ tenofovir alafenamide (TAF) (D/C/F/TAF tablet) relative to continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with tenofovir disoproxil fumarate (FTC/TDF) in virologically-suppressed (human immunodeficiency virus type 1 ribonucleic acid \[HIV-1 RNA\] concentrations less than \[\<\] 50 copies per milliliter \[copies/mL\]) HIV-1 infected participants.
Interventions
- DRUG FTC/TDF
- DRUG D/C/F/TAF
- DRUG Boosted Protease Inhibitor (bPI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,149 participants |
| Start Date | 2015-03 |
| Est. Completion | 2020-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02269917
The ClinicalTrials.gov registry entry for NCT02269917 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen R&D Ireland, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which FTC/TDF is the first listed.
NCT02269917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02269917 about?
NCT02269917 is a clinical study titled "Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants". The purpose of this study is to demonstrate non-inferiority in efficacy while switching to a once-daily single-tablet regimen containing darunavir (DRV)/ cobicistat (COBI)/ emtricitabine (FTC)/ tenofovir alafenamide (TAF) (D/C/F/TAF tablet) relative to continuing the current regimen consisting of a ...
What is the current status of trial NCT02269917?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,149 participants. The study started on 2015-03. Estimated completion is 2020-10.
What interventions are being tested in trial NCT02269917?
The interventions under investigation include: FTC/TDF (DRUG), D/C/F/TAF (DRUG), Boosted Protease Inhibitor (bPI) (DRUG).
Who is sponsoring clinical trial NCT02269917?
This trial is sponsored by Janssen R&D Ireland, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.